Oculis Holding AG OCS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Oculis Holding AG (OCS) is a healthcare company listed in the US with a market value of about $426M. In fiscal year 2025 it had revenue of $2M and net income of -$125M, a net margin of -8253.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -70%.
About Oculis Holding
Oculis Holding is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2020 to $2M in 2025, growth of about 6.0% a year. It was profitable in 0 of the last 6 years in our data.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2M | $757208 | $1M | $987858 | $1M | $1M |
| Net income | -$125M | -$95M | -$106M | -$42M | -$20M | -$17M |
| Free cash flow | -$84M | -$54M | -$66M | -$27M | -$15M | -$14M |
| EPS (diluted) | $-2.24 | $-1.70 | $-1.90 | $-0.75 | $-0.36 | $-0.30 |
| Net margin | -8253.3% | -12503.9% | -10056.9% | -4243.2% | -1932.5% | -1497.8% |
| ROIC | -41.6% | -99.6% | -68.0% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Oculis Holding pay a dividend?
Not currently.
Is Oculis Holding a good stock to buy?
We do not give buy or sell advice. Oculis Holding scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.